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Abstract: Microglia, the major endogenous immune cells of the central nervous system, mediate
critical degenerative and regenerative responses in ischaemic stroke. Microglia become “activated”,
proliferating, and undergoing changes in morphology, gene and protein expression over days and
weeks post-ischaemia, with deleterious and beneficial effects. Pro-inflammatory microglia (commonly
referred to as M1) exacerbate secondary neuronal injury through the release of reactive oxygen species,
cytokines and proteases. In contrast, microglia may facilitate neuronal recovery via tissue and vascular
remodelling, through the secretion of anti-inflammatory cytokines and growth factors (a profile
often termed M2). This M1/M2 nomenclature does not fully account for the microglial heterogeneity
in the ischaemic brain, with some simultaneous expression of both M1 and M2 markers at the
single-cell level. Understanding and regulating microglial activation status, reducing detrimental
and promoting repair behaviours, present the potential for therapeutic intervention, and open a
longer window of opportunity than offered by acute neuroprotective strategies. Pharmacological
modulation of microglial activation status to promote anti-inflammatory gene expression can increase
neurogenesis and improve functional recovery post-stroke, based on promising preclinical data.
Cell-based therapies, using preconditioned microglia, are of interest as a method of therapeutic
modulation of the post-ischaemic inflammatory response. Currently, there are no clinically-approved
pharmacological options targeting post-ischaemic inflammation. A major developmental challenge
for clinical translation will be the selective suppression of the deleterious effects of microglial activity
after stroke whilst retaining (or enhancing) the neurovascular repair and remodelling responses
of microglia.
Keywords: ischaemic stroke; neuroinflammation; microglia; pro-inflammatory; anti-inflammatory;
phenotype
1. Introduction
Ischaemic stroke constitutes about 85% of all stroke events [1]. The underlying pathophysiology of
ischaemic stroke is complex and has not yet been fully elucidated. However, mechanisms underlying
excitotoxicity, inflammatory pathways, oxidative damage, ionic imbalances, apoptosis, angiogenesis
and neuroprotection are widely acknowledged as having a role in ischaemic stroke pathology [2].
The ischaemic cascade is governed by a multitude of molecular events, which variably contribute to
the secondary progression of injury in the post-ischaemic phase [2]. With variable lesion-induced
plasticity, the degree of impairment post-ischaemia differs dramatically between cases, hindering
accurate prognoses [3,4]. As the brain links all of the peripheral organs, brain ischaemia can affect
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function throughout the body, whereas alterations in peripheral organ function also affect the brain.
For example, the immune system is suppressed after ischaemic stroke [5–8], whereas systemic infection
aggravates brain oedema in hypoxia [9]. Up to 95% of stroke patients develop systemic (medical)
complications [10,11] and/or neurological complications, as well as stroke syndromes [12,13]. These
complications are not only a leading cause of death in stroke patients, with a mortality rate between
23% and 50%, but also pose a major challenge for post-stroke treatment and recovery and may delay or
prevent aggressive rehabilitation [10–16].
In the ischaemic brain, microglia, the principal immune cells of the central nervous system
(CNS), produce a plethora of pro- and anti-inflammatory mediators, which have critical roles in both
exacerbating tissue damage [17] and protecting the brain against ischaemic and excitotoxic injury [18].
In contrast to the rapid resident microglial response, blood-derived leukocytes are usually recruited
to the brain parenchyma following a delay of hours to a few days [19]. Therefore, there is an acute
therapeutic window in which microglia represent the key targets for immunomodulatory therapies,
rather than peripheral infiltrating immune cells. The identification of microglia as a key regulatory
factor in ischaemic stroke presents a range of new potential therapeutic targets for neuroprotection [20].
However, the exact contributions of microglia in the context of ischaemic stroke are not yet fully
understood. For example, it is unclear whether microglia can generate beneficial effects in both the acute
and subacute post-ischaemic phases since neuroinflammation has roles in both promoting recovery
and exacerbating secondary neuronal injury [21]. The complex and multiphasic roles displayed by
microglia in ischaemic stroke pathophysiology constitute a major challenge to the development of
immunomodulatory therapies. The aims of this review article were to describe the pathophysiological
roles of microglia following an ischaemic stroke, to summarise the spatio-temporal dynamics of the
signalling cascades underlying microglial biology and to describe potential new therapies for ischaemic
stroke, based on modulating microglial activation and/or microglial transplantation.
2. Microglial Morphology, “Activation” States and Functions in the Brain
Microglia, comprising ~10% of cells in the brain, are the resident mononuclear phagocytes of
the CNS with critical roles in initiating innate and adaptive immune responses [22,23]. Microglia
also contribute to the maintenance of homeostasis within the CNS, including promoting neuronal
survival and mediating synaptic plasticity [24,25]. These roles involve the secretion of trophic
factors, e.g., brain-derived neurotrophic factor (BDNF) [26,27], insulin-like growth factor-1 (IGF-1) [28]
and pruning of neuronal synapses, which involves complement factor C1q [29–31]. Microglia also
remodel the extracellular matrix through the secretion of several proteolytic enzymes, such as matrix
metalloproteases (MMPs) and tissue-type plasminogen activator (tPA) [28].
Microglia are not homogeneously distributed, with the hippocampus, olfactory telencephalon,
basal ganglia and substantia nigra reportedly the most densely populated regions [32]. Regional
microglial heterogeneity may have a role in enabling localised homeostatic functions and region-specific
sensitivities to microglial dysregulation and involvement in age-related neurodegenerative processes
that have neuroinflammatory mechanisms [33,34]. Microglial diversity may be relevant to ischaemic
stroke, for which age is a risk factor and neuroinflammation is present [35,36]. Genome-wide
transcriptional profiling of microglia from discrete brain regions has found that cerebellar and
hippocampal microglia adopt a more immune-vigilant state compared to cortical and striatal regions,
and this has been accompanied by relatively greater expression of an extensive set of co-regulated
genes involved in energy metabolism. Increased expression of genes involved in the immune response
(e.g., Irf7, Stat2, Oasl1, Sp100, Csprs, Isg20, Ifit families, Bst2, Zbp1) has been found in the cerebellum
and hippocampus compared to other brain regions. In addition, the microglial transcriptome has been
found to age in a non-uniform manner across brain regions [33]. This is an important consideration for
the development of microglia transplantation, as the cerebral region from which exogenous microglia
are isolated may have a significant impact on their efficacy.
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The immunological functions of microglia are mediated by changes in cellular activation
status. This has frequently been described in terms of microglial phenotypes, and with reference to
polarisation: microglial populations may be predominantly pro-inflammatory (M1) or predominantly
anti-inflammatory (M2), representing two poles of activation, with an unactivated phenotype in
between (sometimes referred to as M0). These descriptions presumed relative homogeneity within the
microglial populations, such that genes/proteins with increased expression in pro- or anti-inflammatory
conditions have been touted as markers for M1 or M2. However, recent advances have enabled
single-cell transcriptomic analysis of microglia [37]. These data show substantial heterogeneity within
populations, with some cells simultaneously exhibiting M1 and M2 markers, and a lack of consistency
for M2 markers, such that expression of any individual M2 marker has not been strongly correlated
with expression of other M2 markers [37,38]. M1 remains broadly reliable as a description of a
pro-inflammatory activation state, but the label M2 has limited utility for accurately indicating a
gene/protein expression profile [37]. It is likely the M1/M2 nomenclature for microglia will be replaced
in the near future, but the terms are still in widespread use, and so have been used here in the discussion
of the literature, with specific reference to relevant stimuli/markers.
Microglial morphology varies with age, sex and tissue region, but is most strongly influenced
by disturbances to CNS homeostasis [39]. Under normal homeostatic conditions, microglia exhibit
a highly ramified morphology with a small soma (Figure 1). Microglia reside predominantly in
grey matter, with these cells expressing more ramifications than those found in white matter [40],
where microglia typically orientate along nerve fibre tracts and have elongated soma [41]. Although
frequently described as resting, this unactivated phenotype (M0) is highly active, with constantly
moving processes surveilling the immediate surroundings [42–44]. In response to cues associated with
pathogens or tissue damage, microglia typically extend their processes towards these cues [41].Brain Sci. 2020, 10, 159 4 of 21 
 
Figure 1. Morphological features of ramified and amoeboid microglia. The resting-state shows a small 
soma and fine ramified processes (may be referred to as M0, unactivated or homeostatic). Following 
ischaemia, microglia display changes in morphology, retracting their processes and developing a 
large (amoeboid) soma. These morphologies are illustrated for Iba1+ microglia in macaque neocortex 
[43]. 
The M1 phenotype is characterised by high expression of pro-inflammatory mediators [e.g., 
interleukin (IL)-1β, IL-6, tumour necrosis factor-alpha (TNF-α)], the immunoglobulin G (IgG) Fc 
receptors CD16/32 and inducible nitric oxide synthase (iNOS) (Table 1) [57,58]. Pro-inflammatory 
mediators, released by M1-activated microglia, can initiate neuronal apoptosis and blood-brain 
barrier (BBB) disruption [58]. M1 microglia also secrete matrix metalloproteinase (MMP), which 
degrade extracellular matrix proteins and disrupt BBB [40]. Increased BBB permeability promotes 
cerebral vasogenic oedema, haemorrhagic transformation and the leakage of toxic molecules into the 
brain, as well as facilitates the infiltration of circulating neutrophils and macrophages [57,58]. 
Moreover, neurotoxic molecules secreted by M1 microglia can damage neurons and inhibit functional 
recovery [57]. 
The putative M2 phenotype is frequently characterised as displaying greater levels of one or 
more of the following: transforming growth factor-beta (TGF-β), IGF-1, mannose receptor (CD206), 
arginase 1 (Arg1), chitinase-like 3 (Chil3 or Ym1), IL-10 [40,57]. There is increasing evidence that M2 
microglia facilitate tissue repair and remodelling through the production of anti-inflammatory 
cytokines and neurotrophic mediators, which suppress inflammation and facilitate axonal outgrowth 
and angiogenesis (Table 1) [59]. For example, Ym1 and Arg1 limit the degradation of extracellular 
matrix components by MMPs [60]. IL-10 downregulates the production of inflammatory cytokines 
through negative feedback and upregulates the expression of nerve growth factor (NGF) and 
glutathione (GSH), which reduce neuronal death via caspase-3 inhibition [61]. Furthermore, TGF-β1 
upregulates the expression of anti-apoptotic proteins (e.g., Bcl-2, Bcl-x1), thereby promoting neuronal 
survival [62].  
Several studies have described subtypes of M2 activation, based on specific stimuli (singly or in 
combination) in in vitro conditions. M2a activation is triggered by IL-4 and IL-13, which signal 
through IL-4Rα to induce a host of downstream processes that lead to potent anti-inflammatory 
functions, e.g., Arg1 upregulation, inhibition of nuclear factor-kappa B (NF-κB) isoforms and 
production of scavenger receptors for phagocytosis. Exposure to immune complexes and stimulation 
of toll-like receptors (TLR) results in M2b activation. M2b microglia have similarities to M1 microglia, 
e.g., the lack of any M2 specific markers (Arg1, YM1 or FIZZ1), but they do express the typical IL-
10High, IL-12Low M2 cytokine profile. The higher levels of major histocompatibility complex (MHC) II 
and CD86 suggest that M2b microglia can stimulate T cells. M2c activation is stimulated by IL-10, 
glucocorticoids or TGF-β, which activate a phenotype that is involved in tissue remodelling and 
matrix deposition after inflammation has been downregulated [63]. These proposed phenotypes have 
not been reliably demonstrated to occur in in vivo. The high degree of overlap between subtypes 
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Microglia are highly plastic, with their activation status varying as a disease/injury develops and
resolves [45]. Specific stimuli [e.g., ATP, glutamate, cytokines, prostaglandins, zinc, reactive oxygen
species (ROS) and heat shock protein (HSP)60] induce microglial proliferation and chemotaxis. ATP is
an endogenous agonist for the P2X7 purinergic receptor, activation of which has been suggested as a
mechanism for microglial proliferation [46–48]. Upon ischaemic injury, feed-forward ATP-induced
release of ATP from astrocytes is a possible mechanism for activation of microglial P2X7 receptors [49].
Stimulation of microglial glutamate receptors may also be involved in the induction of microglial
proliferation and morphological changes exhibited by microglia in ischaemic conditions [50]. There is
evidence that the mammalian target of rapamycin (mTOR) signalling pathway is involved in microglial
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activation in response to pro-inflammatory cytokines. The mTOR inhibitor RAD001 has reduced
microglial proliferation and viability [51]. Peroxisome proliferator-activated receptor–r (PPAR-r) is a
subtype of PPARs, which are ligand-activated transcription factors of the nuclear hormone receptor
superfamily. Treatment with PPARγ ligands is associated with increased PPARγ expression and
reduced microglial activation and migration to the peri-infarct regions [52,53]. Zinc has been shown to
induce activation of microglia in culture and in the brain; injection of the zinc chelator CaEDTA prevents
ischaemia-induced microglial activation [54]. Reactive species, such as hydrogen peroxide, have also
been associated with an enhanced inflammatory response by microglia. Microglial proliferation can
be stimulated by several pro-inflammatory mediators that are able to directly stimulate microglial
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, leading to subsequent hydrogen
peroxide production, which acts as a mitogenic signal for microglia [55]. Similarly, stimulation of the
triggering receptor expressed on myeloid cells 2 (TREM2) by HSP60 activates morphological changes
in microglia to induce phagocytic activity [56].
The M1 phenotype is characterised by high expression of pro-inflammatory mediators [e.g.,
interleukin (IL)-1β, IL-6, tumour necrosis factor-alpha (TNF-α)], the immunoglobulin G (IgG) Fc
receptors CD16/32 and inducible nitric oxide synthase (iNOS) (Table 1) [57,58]. Pro-inflammatory
mediators, released by M1-activated microglia, can initiate neuronal apoptosis and blood-brain barrier
(BBB) disruption [58]. M1 microglia also secrete matrix metalloproteinase (MMP), which degrade
extracellular matrix proteins and disrupt BBB [40]. Increased BBB permeability promotes cerebral
vasogenic oedema, haemorrhagic transformation and the leakage of toxic molecules into the brain,
as well as facilitates the infiltration of circulating neutrophils and macrophages [57,58]. Moreover,
neurotoxic molecules secreted by M1 microglia can damage neurons and inhibit functional recovery [57].
The putative M2 phenotype is frequently characterised as displaying greater levels of one or
more of the following: transforming growth factor-beta (TGF-β), IGF-1, mannose receptor (CD206),
arginase 1 (Arg1), chitinase-like 3 (Chil3 or Ym1), IL-10 [40,57]. There is increasing evidence that
M2 microglia facilitate tissue repair and remodelling through the production of anti-inflammatory
cytokines and neurotrophic mediators, which suppress inflammation and facilitate axonal outgrowth
and angiogenesis (Table 1) [59]. For example, Ym1 and Arg1 limit the degradation of extracellular matrix
components by MMPs [60]. IL-10 downregulates the production of inflammatory cytokines through
negative feedback and upregulates the expression of nerve growth factor (NGF) and glutathione (GSH),
which reduce neuronal death via caspase-3 inhibition [61]. Furthermore, TGF-β1 upregulates the
expression of anti-apoptotic proteins (e.g., Bcl-2, Bcl-x1), thereby promoting neuronal survival [62].
Several studies have described subtypes of M2 activation, based on specific stimuli (singly or in
combination) in in vitro conditions. M2a activation is triggered by IL-4 and IL-13, which signal through
IL-4Rα to induce a host of downstream processes that lead to potent anti-inflammatory functions, e.g.,
Arg1 upregulation, inhibition of nuclear factor-kappa B (NF-κB) isoforms and production of scavenger
receptors for phagocytosis. Exposure to immune complexes and stimulation of toll-like receptors (TLR)
results in M2b activation. M2b microglia have similarities to M1 microglia, e.g., the lack of any M2
specific markers (Arg1, YM1 or FIZZ1), but they do express the typical IL-10High, IL-12Low M2 cytokine
profile. The higher levels of major histocompatibility complex (MHC) II and CD86 suggest that M2b
microglia can stimulate T cells. M2c activation is stimulated by IL-10, glucocorticoids or TGF-β, which
activate a phenotype that is involved in tissue remodelling and matrix deposition after inflammation
has been downregulated [63]. These proposed phenotypes have not been reliably demonstrated to
occur in in vivo. The high degree of overlap between subtypes suggests that microglia exist as a
spectrum of phenotypes depending on external stimuli, so we have focused on the M2 phenotype as a
whole as a therapeutic target for ischaemic stroke.
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Table 1. Roles of Microglia in Ischaemic Stroke.
Biological Process Mediators Effects Potentially BeneficialPost-Ischaemia
Effects Potentially Deleterious
Post-Ischaemia
Pro-inflammatory
TNF-α Possibly neuroprotective; exacerbated infarctin TNF-α-/- KO mice [64] Exacerbated infarct volume, oedema [58,65]
Inflammasome
In ischaemic conditions, NLRC4
inflammasome complex induces pyroptotic
microglial death, exacerbating inflammatory
damage [66]
NLRC4-/- KO mice have lesser neurological
deficits post tMCAo [67]
NLRP3-/- KO mice have lesser BBB
breakdown, infarct size, oedema,
neurological deficits post tMCAo [68]
IL-1β, IL-6,
IL-12, IL-23,
IFN-γ
Prolonged/heightened inflammation.
Bystander tissue damage [66]
Anti-inflammatory TGF-β, IL-4,IL-10, IL-13
Reduced inflammatory damage.
Pro-regeneration. Upregulated Bcl-2, Bcl-x1.
Enhances dendritic spine formation and
synaptogenesis in cultured neurons and
provides negative feedback in the production
of inflammatory cytokines. Inhibit the
activity of caspase-3, upregulate the level of
GSH and NGF [69]
Chemotaxis
CD11b, CD16,
CD32,
CCL2/MCP1
Facilitate microglial migration to injury
sites [70]
CCL2-/- KO mice show decreased injury
post-ischaemia [59]; anti-CD11b antibody
reduced infarct size in rat tMCAo [71]
Phagocytosis CD11c (ITGAX)
Clears damaged cells, neurotoxic molecules
and molecules inhibitory to repair. Early
infiltrating macrophages are CD11c−, but
CD11c+ macrophages may outnumber
CD11c+ microglia by 3 d post-stroke [63].
Dendritic cells are CD11c+ [72]
Microglia may phagocytose damaged
neurons, which could otherwise have
recovered [73,74]
ROS, RNS iNOS, NO−
Disrupts BBB, facilitating infiltration of
peripheral immune cells and toxic molecules
from serum. Oxidises PS on the surface of
neurons and promotes neuron loss through
phagocytosis. Exacerbates glutamate
excitotoxicity. Damaging to oligodendroglia.
Anti-oxidants GSH, HO-1
Inhibit oxidation of PS and promote neuron
repair by reducing the phagocytic capacity of
microglia [59]
ECM-degrading
enzymes
MMP-3,
MMP-9
Degrade extracellular matrix proteins, reduce
the integrity of BBB; MMP-9 upregulated by
signals from serum [75]
Angiogenesis
VEGF, BDNF,
progranulin,
MMP-9
Facilitate axonal outgrowth and angiogenesis.
MMP-9 degrades chondroitin sulphate
proteoglycan, a component of the EC matrix
that is reported to inhibit axonal growth [59]
Microglia express VEGF receptor; VEGF is
associated with increased BBB
permeability [76]
Neurotoxic
molecules Glutamate
Neurotoxic; microglia upregulation of
GluR2-4 AMPA receptors is associated with
axon and oligodendrocyte damage [77]
Neuroprotective
molecules
bFGF Promotes mitosis of oligodendrocyteprecursor cells [78]
IGF-1, GDNF,
thrombospondins,
erythropoietin
Promote plasticity [79]; thrombospondins
may be more highly expressed in
macrophages [80]
BDNF
~30% OX42+ cells expressed BDNF
post-ischaemia; associated with plasticity
(neuronal regeneration) [79]
Arg1, Arginase 1; BDNF, brain-derived neurotrophic factor; bFGF, basic fibroblast growth factor; GDNF, glial
cell-derived neurotrophic factor; GSH, glutathione; HO-1, heme oxygenase; IGF-1, insulin-like growth factor 1;
IL-1β, interleukin-1β; IL-13, interleukin-13; IL-4, interleukin-4; IL-6, interleukin-6; IL-10, interleukin-10; IL-12,
interleukin-12; IL-23, interleukin-23; iNOS, inducible nitric oxide synthase; MMP-3, matrix metalloproteinase-3;
MMP-9, matrix metalloproteinase-9; NGF, nerve growth factor; NLRC4, neuronal apoptosis inhibitory protein
(NAIP)/NOD-like receptor 4; NO, nitric oxide; PS, phosphatidylserine; ROS, reactive oxygen species; TGF-β,
transforming growth factor-β, tMCAo, transient middle cerebral artery occlusion. TNF-α, tumour necrosis factor- α;
VEGF, vascular endothelial growth factor.
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3. Microglial Responses in Ischaemic Stroke
Following an ischaemic stroke, distinct regions of cerebrovascular pathology can be identified. In
the infarct core, brain cells die from necrosis. Neuronal death stimulates the release of damage-associated
molecular patterns (DAMPs), including exogenous peptidoglycans, endogenous HSP and non-protein
molecules, e.g., ATP and nucleic acid molecules [81]. DAMPs elicit a strong inflammatory response
by activating pattern recognition receptors (PRRs), e.g., TLR1-9 [82]. Activation of PRRs induces
intracellular signal transduction pathways, thereby modulating microglial activation, e.g., NF-κB
signalling pathway, and Toll/IL-1 receptor (TIR)-domain-containing adapter-inducing interferon-β
(TRIF) that induces interferon regulatory factor-3 (IRF3) signalling pathway [83]. Microglia express
several receptors, which can recognise DAMPs: TLRs, nucleotide-binding oligomerisation domain
(nod)-like receptors (NLRs) and the retinoic acid-inducible gene-1 (RIG1)-like receptors (RLRs).
Surrounding the ischaemic core, the penumbra is a region of potentially salvageable tissue, where
the apoptotic signal pathways are initiated, e.g., mitochondrial release of cytochrome c initiates
caspase-mediated neuronal apoptosis [84]. Cells of the penumbra undergo a substantial morphological
and metabolic transformation, along with rapid and profound genetic upregulation [2]. Furthermore,
glutamate, an excitatory neurotransmitter, is released by neurons in response to ischaemia and activates
glutamate receptors on microglia [85].
Post-ischaemia, microglia rapidly migrate to the lesion site, proliferate, display altered gene
and protein expression profiles and undergo morphological changes [40,43,86]. Microglia develop
macrophage-like capabilities, including phagocytosis, cytokine production, antigen presentation and
the release of MMPs, which cause disruption of the BBB [40]. Breakdown of BBB allows peripheral
macrophages and neutrophils to infiltrate cerebral tissue [40]. The main sources of macrophages
infiltrating into ischaemic brain tissue after stroke include microglia-derived macrophages (MiDM)
and monocyte-derived macrophages (MoDM). Peripheral monocytes are migrated through the BBB to
the ischaemic brain under the action of chemokines and cell adhesion molecules [87].
The post-ischaemic proliferation of microglia peaks at 48 to 72 h after focal cerebral ischaemia, but
may last for several weeks [67]. Both CD11b and CD206 have been detected in the mouse brain as
early as 6 h after transient middle cerebral artery occlusion (tMCAo) [88], whereas both M1 markers
(CD32, CD16, iNOS, CD11b, CD86) and M2 markers (CD206, IL-10, YM1/2, TGF-β, Arg1, CCL22) have
been observed in the mouse brain between 1 and 14 d after tMCAo [89]. CD16/32, an M1 marker,
has increased over time, whereas CD206, an M2 marker has appeared in the ischaemic core at 24 h,
peaking at 5 d, and declining in the striatum by 14 d [89]. Days 2–7 following ischaemia, a phenotypic
shift from M2 to M1 microglia has been observed in the infarct core [89]. In the core region, M2
microglia levels diminish after 3–7 d with some remaining in the penumbra. M1 cells have been found
to increase in number in the striatum over time and eventually outnumber the M2 cells throughout the
second week [86]. This shift in location suggests microglia move from the core once necrotic debris is
phagocytosed [88]. In the penumbra, microglia are further activated, proliferate, migrate to repopulate
the core. In months following ischaemia, there is evidence of long-term activation of microglia in both
the penumbra and the unlesioned tissue, leading to secondary neuronal damage [90].
Microglia, which possess a strong phagocytic capacity, can contribute to the removal of necrotic
neurons, tissue debris and disabled synapses, thus preventing secondary inflammation and promoting
remodelling after stroke [58,81,83]. The elongated shape and high expression levels of F-actin expressed
by M2 microglia facilitate phagosome formation and motility [84]. Microglia that exhibit anti-oxidative
responses, including suppressing the post-ischaemic level of ROS, and upregulating GSH and heme
oxygenase-1 (HO-1), which inhibit oxidation of phosphatidylserine (PS), promote viable neuron
repair [70]. In contrast, microglia that possess high levels of ROS have an increased capacity to
phagocytose potentially viable neuron [85,87].
A key therapeutic aim of future stroke agents would be counteracting the delayed post-acute shift
in microglia activity from an M2 phenotype to M1 without causing complete or chronic inhibition of
the inflammatory response. Reducing deleterious actions of microglia at the peri-infarct regions may
Brain Sci. 2020, 10, 159 7 of 22
prevent potential damage to healthy BBB endothelium, thereby reducing the potential for peripheral
leucocyte infiltration.
4. Pharmacological Modulation of Microglia Activation in Ischaemic Stroke
Currently, there are no pharmacological treatments approved to target ischaemia-induced
inflammation in stroke. Microglial modifying agents administered post-stroke could provide a
promising therapeutic strategy for ischaemic stroke [57]. A number of pharmaceutical agents aiming to
target distinct microglial markers in ischaemia have shown promising results in experimental studies
and clinical trials. Considering the high disease burden of ischaemic stroke, drug repurposing of
pre-existing pharmaceutical agents may be an avenue for exploration in addition to the development
of new therapeutic agents, which specifically target the phenotypic expression of microglia [1]. It is
worth noting that many of these agents have been administered orally and could affect both infiltrating
peripheral macrophages and endogenous microglia. It has historically been difficult to differentiate
between resident microglia and infiltrating macrophages in the parenchyma of the post-ischaemic
brain [91]. It is likely the cells, described as microglia in the literature cited below, are in reality a mix of
locally recruited microglia and infiltrating peripheral macrophages. These two populations have been
treated as one in the following discussion, as we were interested in the neuroinflammatory response as
a potential therapeutic opportunity rather than the phenomenological characterisation of microglia
per se.
4.1. Minocycline
Minocycline, a tetracycline-derived antibiotic, is highly lipophilic, so is able to penetrate the
BBB [92]. The anti-inflammatory effects of minocycline are thought to occur through the inhibition
of iNOS and via the mitogen-activated protein kinase (MAPK) p38 in microglia [93]. Alternatively,
other studies have noted inhibition of MMP activity (particularly MMP-9) and apoptotic pathways
as other important mechanistic biomarkers for minocycline [94]. Minocycline inhibits the enzymatic
activity of MMP-2 and MMP-9 and at low dose is selective for MMP-9. MMP-9 inhibition presents a
therapeutic potential for ischaemic stroke since its production by M1 microglia has been associated with
demyelination and axonal injury [95]. Anti-apoptotic effects of minocycline are attributed to reduced
cytochrome c release from mitochondria and inhibition of the apoptotic drivers, caspase-1 and -3, as
well as enhancement of Bcl-2 [96]. Additionally, a decrease in M1-like microglial responses, including
IL-1β, ROS, NO and glutamate generation, has also been associated with minocycline treatment [96].
Minocycline has also been found to attenuate expression of inflammatory genes (e.g., IL-6, IL-1β, MHC2
and TLR-2) and inhibit pro-nerve growth factor production by microglia [96].
The efficacy of minocycline has been studied in animal models of acute neurologic injury.
Minocycline has been shown to reduce the number of CD68+ cells within the peri-infarct tissue at
3 days following photothrombotic stroke and improve neurological outcomes and reduce infarct
volume [97]. However, Tsuji et al. reported that minocycline exacerbated hypoxic-ischaemic brain
injury [98]. Hanlon et al. found minocycline treatment had no effect on traumatic tissue atrophy or
spatial learning deficits in a rat model of abusive head trauma [99]. Furthermore, minocycline-treated
rats have demonstrated exacerbated injury-induced memory deficit [99]. These deleterious effects
could be in part explained by minocycline’s effect on mitochondrial function. Minocycline impairs
mitochondrial function by depleting endogenous mitochondrial magnesium, inducing permeability
of the inner mitochondrial membrane, triggering mitochondrial swelling and cytochrome c release
and abolishing the calcium retention capacity of rat liver mitochondria [100]. Diguet et al. advocated
caution when considering clinical use of minocycline for CNS disorders [101].
To date, a number of clinical trials of minocycline for use in ischaemic stroke have been conducted
with varying degrees of success. Minocycline has shown improved functional recovery and reduced
disability and dependence at 90 d post-stroke in two randomised single-blinded studies: ‘minocycline
in acute stroke’ [102] and ‘efficacy of minocycline in acute ischaemic stroke: a single-blinded,
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placebo-controlled trial’ [103]. In 2010, the dose-escalation study ‘minocycline to improve neurological
functional outcome’ (MINOS) [104] found that minocycline was efficacious at lower doses (3 mg/kg).
A total of 72.8% of patients had an modified Rankin Scale (mRS) score of 0–1 equating to very limited
symptoms and being able to carry out all usual daily living activities compared to 75% at 4.5 mg/kg,
50% at 6 mg/kg and 41.5% at 10 mg/kg. However, the outcome was not corroborated by the 2013 study
‘intravenous minocycline in acute stroke: a randomised, controlled pilot study and meta-analysis’ [105],
which did not find a significant difference in surviving patients free of disability (Mrs ≤ 2) in the
patient group receiving intravenous minocycline compared to the control group who received routine
treatment. The effect of minocycline on plasma MMP-9 in the MINOS trial and a comparison group
of no minocycline was investigated in ‘MMP-9 in an exploratory trial of intravenous minocycline
for acute ischaemic stroke’ [106]. In MINOS, intravenous minocycline reduced MMP-9 levels at 72 h
compared to baseline routine treatment (tPA, p = 0.0022; non-tPA, p = 0.0066) and was lower than in the
non-MINOS comparison group at 24 h (tPA, p < 0.0001; non-tPA, p = 0.0019). Plasma levels of MMP-9
were amplified by tPA. High levels of MMP-9 were associated with increased risk of tPA-related
haemorrhage and increased neurologic severity. Lower plasma MMP-9 was seen among tPA-treated
subjects in the MINOS trial, and, therefore, concomitant minocycline and tPA treatment might be a
therapeutic strategy to prevent the adverse effects of thrombolysis via suppression of MMP-9 activity.
A multi-centre randomised, double-blind, placebo-controlled trial, ‘neuroprotection with
minocycline therapy for acute stroke recovery trial’ (NeuMAST) [94,107], did not find evidence for
minocycline’s efficacy in improving long-term recovery, and the trial was abandoned in May 2013 after
an interim analysis. ‘An open-label evaluator-blinded clinical study of minocycline neuroprotection in
ischaemic stroke: gender-dependent effect’ [108] studied the neuroprotective properties of minocycline
in ischaemic stroke. Oral minocycline administration improved functional outcomes in terms of NIHSS
(National Institutes of Health Stroke Scale/Score; higher scores indicate greater impairment) in a 90 d
follow up, but efficacy was only demonstrated in male patients. However, the small sample size of
53 patients and the single-blinded nature reduced the reliability of the trial results. Furthermore, the
gender-specific outcome of the trial was not supported by the aforementioned study ‘MMP-9 in an
exploratory trial of intravenous minocycline for acute ischaemic stroke’ [106], which used females and
males at a ratio of 13:10 in the treated group and a ratio of 18:9 in control and, still, demonstrated
minocycline’s efficacy in reducing NIHSS.
4.2. Metformin
Metformin acts by decreasing gluconeogenesis and increasing peripheral utilisation of glucose,
thereby improving glucose levels in type 2 diabetics. Metformin has been found to exert neuroprotective
effects when given to rodents prior to middle cerebral artery occlusion (MCAO) for a prolonged period
(7 d or 6 weeks), but this effect has not been observed when metformin is administered for a shorter
duration (1 d or 3 d) [109,110]. Jia et al. [111] concluded that metformin might even have a beneficial
effect when given post-stroke as it stimulated adenosine monophosphate (AMP)-activated protein
kinase (AMPK) and alleviated stroke-enhanced serum glucose levels. Jin et al. [112] reported increased
angiogenesis and neurogenesis and improved functional recovery following metformin treatment post
tMCAo. Since AMPK coordinates control of cell growth and autophagy [113], the neuroprotective
effects could be due to autophagy induced by metformin [114]. Furthermore, metformin has also
been shown to inhibit NF-κB cascade and suppress neuroinflammation [115,116]. Post-stroke, chronic
metformin treatment has suppressed the expression of ‘M1’-associated genes (CD32, IL1b, CD16)
and enhanced the expression of ‘M2’-associated genes (CD206, Arg1) [58]. A clinical trial in patients
with ischaemic stroke showed a significant decrease in NIHSS score in patients who were given
metformin [117].
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4.3. Statins
Statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme-A reductase, have been shown to
inhibit inflammatory cell recruitment, adhesion, and migration [118]. Statins reduce inflammatory
biomarkers and inhibit the activation of inflammatory transcription, leading to neuroprotection.
Simvastatin has been linked to altered cytokine secretion (IL-1β and TNF-α) and upregulated endothelial
NOS (eNOS) [119]. In addition, statins are thought to exhibit antioxidant effects via ROS production
inhibition and have beneficial effects on endothelial function, coronary and cerebral blood flow and
haemostasis [120,121]. Atorvastatin has been found to promote angiogenesis and enhance functional
recovery after stroke by promoting cerebral blood flow [122]. Pre-treatment with rosuvastatin has similar
outcomes to minocycline, in terms of improved neurological score and reduced infarct volume [119].
A prospective, non-randomised patient study found that rosuvastatin treatment improved NIHSS
scores (OR of 0.04 for NIHSS score of 15 (95% CI, 0.003 to 0.93)) and reduced mortality (OR of
0.20 (95% CI, 0.02 to 1.67)) in intracerebral haemorrhage (ICH) [123]. The mechanism underlying
rosuvastatin’s efficacy in stroke may be related to its ability to modulate microglial activation status,
upregulate anti-inflammatory cytokines (IL-10) and suppress pro-inflammatory gene expression (IL-1β,
TNF-α) [124]. The safety and efficacy of rosuvastatin were investigated in the ‘effects of very early
use of rosuvastatin in preventing recurrence of ischemic stroke [EUREKA]’ trial. Diffusion-weighted
imaging showed no significant difference in the development of new ischaemic lesions between the
rosuvastatin-treated group and the placebo control group. Furthermore, parenchymal/subarachnoid
haemorrhage on gradient-recalled echo magnetic resonance imaging occurred less frequently in the
rosuvastatin group [125]. A recent multicentre clinical trial—‘stroke treatment with acute reperfusion
and simvastatin’ (STARS07), found that statin-tPA therapy was safe but not efficacious in acute
stroke [126]. Lovastatin has been found to be clinically safe at doses above the recommended U.S.
Food and Drug Administration (FDA) approved dose in phase 1 dose-escalation study. The maximum
tolerated dose has been estimated to be 8 mg/kg/day for 3 days after an acute ischaemic stroke [127].
Furthermore, an ongoing phase 2, randomised safety study involving ischaemic stroke patients aimed to
compare the effects of placebo or standard dose lovastatin versus short-term high-dose lovastatin [128].
The primary outcome of this study was the occurrence of myotoxicity and neurological outcomes, and
effects on inflammatory markers and lipid levels would also be assessed. However, the results of this
trial are not yet in the public domain.
4.4. Indomethacin
Indomethacin is a non-steroidal inflammatory drug that is indicated for osteoarthritis and
rheumatoid arthritis. Lopes et al. [129] found that indomethacin treatment in rats with endothelin-1
(ET-1)-induced focal striatal ischaemia inhibited microglial activation at 8- and 14-d post-injury.
Indomethacin administration was correlated with increased numbers of neuroblasts in the
subventricular zone (SVZ) post-stroke mainly at 14 d post-stroke but did not significantly affect
neuronal density or increase the neuroblast population in the infarct area. Similarly, Sandu et al. [130]
found that indomethacin administration demonstrated neuroprotective efficacy by increasing the
survival of penumbral neurons and by decreasing the infarct size after transient focal ischaemia.
Indomethacin was also found to decrease the ED1+—activated macrophages/microglia in the infarct
core in the young rats and increased the number of proliferating microglia in the peri-infarct region.
Bok et al. [131] concluded that indomethacin significantly attenuated CD68-positive microglial activation
in a mouse model of focal cerebral ischaemia. Comparably, indomethacin has been found to enhance
neurogenesis in rats exposed to focal ischaemia: increased numbers of bromodeoxyuridine (BrdU)
positive cells of all lineages have been found, with reduced microglial/monocyte activation [132].
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4.5. Noggin
Noggin has been shown to prevent brain atrophy and improve functional outcomes through the
inhibition of bone morphogenetic protein signalling during the later phases of cerebral ischaemia in
mice [133]. Noggin has also been found to augment brain repair processes, including resolution of
scar formation, axonal sprouting and angiogenesis, as well as to increase microglial activation and
modulate microglial phenotypes to induce a switch from M1 to M2 [134].
4.6. PPAR-R
Activation of PPAR-r results in insulin sensitisation and enhances glucose metabolism [135].
PPAR-r has the ability to inhibit the expression of inflammatory cytokines and direct the differentiation
of immune cells towards anti-inflammatory phenotypes. 1,25-D3 pretreatment activated PPAR-r,
reduced NF-κB and TNF αexpression, improved neurological functions in the rat after tMCAo [136].
Activation of PPAR-r has also been shown to inhibit the expression of iNOS and inflammatory cytokines
and to reduce ROS formation [133]. A review of five random-control trials, which investigated the
effects of PPAR-r agonists in the prevention of stroke recurrence, was conducted. Although PPAR-r
agonists have reduced the recurrence of stroke, their effects on adverse events remain uncertain.
However, due to the small number of included studies, limited quality of available study data and
the fact that the data was not meta-analysed, the results of the review should be interpreted with
caution [137].
4.7. TNF-α Antagonists
Tumour necrosis factor (TNF) is an immune signalling molecule, centrally involved in ischaemic
stroke pathology through its modulation of microglial activation, role in synaptic dysfunction and
induction of depressive symptoms and neuropathic pain. Etanercept, a recombinant TNF receptor
fusion protein and potent TNF inhibitor, has been found to produce an immediate, significant and
sustained improvement in neurological outcomes in patients with chronic neurological dysfunction
present for more than 3 years following acute brain injury [138]. This is consistent with a study by
Wu et al. [139], in which etanercept markedly reduced cerebral infarct, BBB disruption and neurological
motor deficits in rats subjected to tMCAo, and this effect was more pronounced when combined
with alpha-lipoic acid. A greater decrease in the serum levels of TNF-α, as well as the brain levels
of microglial activation, was observed with the combined drug treatment compared to the separate
administration of the drugs. Banno et al. [140] found that edaravone significantly suppressed the
production of NO and ROS by activated microglia, though it did not suppress the production of
inflammatory cytokines. Edaravone significantly suppressed neuronal cell death and dendrotoxicity
induced by either the peroxynitrite donor N-morpholinosydnonimine or activated microglia in a
dose-dependent manner. Edaravone has been shown to scavenge free radical in acute ischaemic
stroke patients in Japan [141]. However, Isahaya et al. [142] found no significant differences in serum
concentrations of TNF-α between ischaemic stroke patients treated with edaravone compared to
controls. Nevertheless, edaravone was found to significantly suppress circulating MMP-9 in patients
with acute ischaemic stroke. MMP-9 is involved in the pathogenesis of vasogenic brain oedema due
to its effect on vascular endothelial permeability, thus offering a further mechanism underlying the
efficacy of edaravone in stroke.
4.8. Fingolimod
The sphingosine-1-phosphate regulator (S1P), fingolimod, approved by the FDA in 2010 for the
treatment of Multiple Sclerosis was studied in phase II clinical trial for the treatment of stroke [143].
Fingolimod is thought to exert its mechanism by binding to the S1P1 receptor and inhibiting downstream
signalling pathways. Signal transducer and activator of transcription 3 (STAT3) inhibition has been
suggested as a possible mechanism underlying fingolimod’s efficacy. STAT3 ordinarily elevates NF-κB
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and pro-inflammatory gene expression. Fingolimod may also downregulate histone deacetylase
(HDAC) activity, which further suppresses NF-κB activation, resulting in the downregulation of
pro-inflammatory cytokines (e.g., TNF-α, IL-1β), and promotes the expression of neurotrophic factors
(e.g., BDNF and glial cell-derived neurotrophic factor (GDNF)), which aid neurogenesis. The lipophilic
nature of fingolimod enables it to pass through the BBB, and there is evidence that fingolimod can alter
the function of brain cells [144].
4.9. Colony Stimulating Factor Receptor Inhibitors
Colony-stimulating factor receptor 1 (CSF1R) is activated by CSF1 (macrophage CSF) or IL34 and
is expressed by cells, including monocytes, dendritic cells and peripheral macrophages. Within the
CNS, CSF1R is reportedly predominantly expressed in microglia, in contrast to other cell types [145].
CSF1R inhibitors ablate microglia and have recently been used to suppress microglia reactivity in
different conditions [146]. CSF1R inhibitors, such as PLX3397, BLZ945 and GW2580, have been
administered orally to deplete microglia in the CNS [147]. PLX3397 transiently eliminates ~99% of
microglia in the adult mouse brain without any detectable behavioural or cognitive impairment, and
the microglia population recovers after cessation of CSF1R blockade [148,149]. CSF1R inhibition
reduces neuroinflammation, leading to improved disease phenotype in mouse models of Alzheimer’s
disease [150–152]. However, Szalay et al. [153] demonstrated that selective elimination of microglia in
mice led to a striking 60% increase in infarct size following tMCAo, which was reversed by microglial
repopulation. CSF1R inhibition has been reported to exacerbate post-ischaemic outcomes in a mouse
model of brain ischaemia, through increased production of pro-inflammatory cytokines [154]. Microglia
depletion by long-term treatment with a CSF1R inhibitor, PLX5622, has increased the numbers of
neutrophils and enlarged the ischaemic lesion [155]. These adverse responses to experimental depletion
in microglial activity highlight the beneficial role of microglia in ischaemic stroke.
5. Cellular Therapies for Stroke That Target Microglia
Ischaemic injury in the brain is believed to be mediated by several mechanisms, thus supporting
research into a multi-target therapeutic strategy, such as using cell-based therapies involving
bone marrow-derived mesenchymal stem (BMSCs) or the direct administration of microglia [156].
Translocator protein (TSPO) has been used as a non-selective biomarker of microglial activation in
positron emission tomography (PET) to show the proportion of systemically administered microglia,
which are able to cross the BBB [143]. The adhesion receptor macrophage-1 antigen (Mac-1) mediates the
adhesion of microglia to the endothelial surface, thus providing a possible mechanism for the infiltrating
properties of microglia across the BBB [157]. Mac-1 is a β2 integrin that is constitutively expressed on
the surface of microglia. Mac-1 upregulation after oxygen-glucose deprivation (OGD) preconditioning
has been found to enable microglia to cross the BBB and reach the rat brain parenchyma [69]. In
addition, a study in C57BL/6 mice revealed that M2-like macrophages were able to infiltrate the
ischaemic hemisphere via the choroid plexus-cerebrospinal fluid (CSF) route, thus suggesting that
autologous transplantation of M2-like microglia into the CSF might be a promising treatment strategy
for ischaemic stroke [158]. Apart from the epithelial cells of the choroid plexus, there are two other
routes for leukocyte migration from the blood into the brain parenchyma, i.e., BBB and the meningeal
blood circulation, each of which could be exploited by microglia [159,160].
Studies on direct administration of primary microglia and cell-line microglia in animal models
have demonstrated improved axonal outgrowth, reduced infarct size and improved functional
outcomes post-stroke. Imai et al. [161] concluded that administration of exogenous microglia after
ischaemia protected against ischaemic injury in vivo and improved ischaemia-induced learning deficits.
Ekdahl et al. [162] found that microglia pre-conditioned to a protective phenotype could support
neurogenesis, progenitor proliferation and survival, migration and differentiation of newly formed
neurons in the adult brain following stroke. Kanazawa et al. [69] found that intrathecal administration
of primary microglia preconditioned in OGD conditions promoted the secretion of remodelling factors
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into the brain parenchyma, e.g., vascular endothelial growth factor (VEGF), TGF-β and MMP-9,
thus facilitating axonal outgrowth and angiogenesis in the ischaemic cortex of rats. Administration
of M1-polarised microglia has exacerbated OGD-induced neuronal death, manifested by reduced
microtubule-associated protein-2 (MAP2) expression and increased lactate dehydrogenase (LDH)
release, compared to microglia expressing differing inflammatory profiles. Similarly, HMO6 human
microglial cell transplantation has significantly reduced ischaemic deficits and apoptotic events in rats
exposed to MCAO. The results have been mediated by modulation of gliosis and neuroinflammation,
as well as neuroprotection provided by neurotrophic factors and anti-inflammatory cytokines of
endogenous and transplanted microglia [161]. However, it is still not known whether functional
recovery is directly due to the transplanted cells or whether the cells induce peripheral immune cells
to alter cytokine release [163].
In clinical trials, however, Chernykh et al. [164] found that intrathecal autologous M2 macrophage
transplantation in nonacute stroke patients did not significantly affect cytokine production. However,
75% of patients exhibited an improved NIHSS score by≥3 versus 18% in the control group. Furthermore,
responder patients had lower spontaneous production of IL-10, fibroblast growth factor-β (FGF-β),
platelet-derived growth factor (PDGF) and VEGF and higher stimulation indexes of IL-1β, TNF-α, IFN-γ
and IL-6 than non-responders, thus suggesting that the improved neurological activity associated with
autologous M2 cells might be mediated through the immunomodulatory activity of M2 macrophages.
In contrast, a phase II, randomised controlled trial, in which subacute ischaemic stroke patients received
BMSCs (a mean of 280.75 million at a median of 18.5 d after stroke onset), concluded that whilst an
intravenous infusion of BMSCs is safe, there was no beneficial effect on stroke outcome [164]. Further
studies should seek to establish if a dose-effect relationship exists, as the failure could be due to an
insufficiency in the dose administered. It is also possible that at the time of administration of BMSCs at
a median of 18.5 d after stroke onset, the amount of cerebral damage may have already reached its
peak. In addition, this trial used the intravenous route to administer cell therapy. The relative efficacy
of this route of delivery should be compared to other routes, such as the intra-arterial or intracerebral
route [165]. Yang et al. [166] concluded that intravenous administration of stem cells in rats with
tMCAo achieved a similar functional outcome post-stroke to intra-arterial administration. The lack
of clinical efficacy in human studies may also be attributable to the non-polar status of the BMSCs.
Hu et al. [89] found that when microglia of different phenotypes were mixed with neurons in a 1:10 ratio
prior to administration, both M2 and non-polarised microglia promoted survival of cortical neurons
following focal cerebral ischaemia, suggesting a cell-cell contact-mediated protective mechanism.
6. Challenges for Stroke Therapies Targeting Microglia
Since much of the research on microglia “activation” is performed in vitro, interpretation and
generalisation of the results must be done with caution. Many pre-clinical studies use microglia derived
from neonatal tissue and matured in culture-medium, which does not replicate the complex in vivo
maturation process [57]. The culture medium is typically supplemented with 10% (bovine) serum in
experimental studies, whereas endogenous microglia are not exposed to serum components, given an
intact BBB [167]. It is widely accepted that, in the brain, microglial activity is controlled by inhibitory
inputs (e.g., CX3CL1, CD200, CD22 and CD172), which are typically absent in culture. In animal
models, the genetic removal of even just one of the factors inhibiting microglial activation dramatically
alters the activation profile of microglia and, in many instances, has demonstrated inappropriate
activation, including toxic responses. As a result, it must be considered that the absence of these factors
in vitro could have a significant impact on the activation status of cultured microglia [168].
Laboratory experimentation may generate different activation profiles from those found in
live human brain tissue following a stroke, as in vitro cultures commonly demonstrate amoeboid
morphologies and are generally considered to exhibit signs of low-level inflammatory activation [169].
Therefore, it may be more scientifically sound to caution against attempts to classify microglial
populations as exhibiting a distinct phenotype and instead view microglial “activation” as specific
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to individual cells [60]. The classification of microglia is currently under discussion with Ransohoff,
arguing that the elucidation of regional and age-dependent microglial profiles does not support the
notion that microglia will adopt a single state transcriptomic profiles (relating to M1 and M2) under
physiological or stress conditions [168]. Whilst frequently portrayed as a single event or a homogenous
phenotype, activation of microglia post-ischaemia may be more accurately depicted as a continuum of
events, with the heterogeneity of marker expression among the microglial population [44].
One of the fundamental hurdles in existing research targeting microglia is that the underlying
mechanisms regulating microglial activation are not yet fully understood. Whilst an abundance of
pathways and mediators have been identified as regulators of macrophage activation, the assumption
that microglial activation is regulated by the same mechanisms cannot necessarily be made. The majority
of these signalling pathways appear to overlap and seem to work synergistically with one another,
as opposed to functioning independently. In addition to this, the aforementioned spatio-temporal
dynamics of microglial activation must also be accurately mapped in order to establish the optimum
time to administer therapy.
Although experimental stroke treatments continue to fail in human clinical trials, the
inflammatory/immune responses after cerebral ischaemia are shared between the animal models and
patients [170]. Combined with complementary knowledge from in vitro studies, animal models can
provide valuable insight into stroke pathology at a system level [171]. A deeper understanding of the
in vivo physiological changes post-ischaemia is required to identify further treatment targets for stroke.
Current research suggests that upon “activation”, microglia potentiate BBB disruption, thus exposing
the brain to systemic responses, such as peripheral infiltration of leukocytes into cerebral tissue [40].
Understanding the mechanism by which microglia increase BBB permeability could provide a focus
for future research on improving drug delivery into the ischaemic brain [172].
7. Conclusions
Although progress continues to be made in the prevention, treatment and rehabilitation of those
affected by stroke, there remains a significant capacity for improvement. With such a complex and
multifaceted pathophysiology, targeting the mechanisms by which stroke is known to cause cerebral
damage remains a significant barrier to achieving pre-stroke functionality. At present, many patients
who survive an ischaemic attack experience a decline in their quality of life, developing conditions, such
as hemiplegic paralysis and aphasia [1]. Microglial biology plays a pivotal role in the pathophysiology
of neuroinflammation induced by ischaemic stroke, thus presenting an attractive treatment target for
pharmacological intervention. However, pharmacological treatments targeting microglial activation
remains sub-optimal. A greater understanding of the heterogeneity of phenotypes at a cellular level,
as well as the functional impacts of these on a regional level, could inform the development of novel
therapies and perhaps improve current treatment regimens, thereby alleviating post-ischaemic damage
whilst promoting the reparative functions of microglia [173]. Stimulating cerebrovascular tissue repair
may be achievable by targeting distinct microglial populations, focusing heavily on the temporal
and spatial aspects of the post-ischaemic response. Modulation of microglial activation status or
transplantation of exogenous microglia pre-conditioned with specific stimuli may reverse the neuronal
loss and repair neural networks, thus presenting a therapeutic approach to prevent functional disability
in stroke survivors. Harnessing the regenerative role of microglia, whilst avoiding the deleterious
effects of total immunosuppression, merits further investigation.
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